Esketamine Combined With PRF of DRG for Acute/Subacute Zoster-associated Pain

NANot yet recruitingINTERVENTIONAL
Enrollment

184

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

April 1, 2026

Study Completion Date

July 1, 2026

Conditions
Herpes Zoster
Interventions
DRUG

esketamine group

in addition to receiving the combination of PRF of DRG and standardized drug treatment, patients will also undergo a single intravenous infusion of esketamine.

DRUG

PRF group

In the control group, patients will receive PRF+standardized drug treatment. Pulsed radiofrequency (PRF) will be performed on DRG by an designated physician in each participating center. They will be treated with PRF (PMG-230, Baylis Medical Inc.) using a 21-gauge sterilized radiofrequency needle (a 10-cm trocar with a 5-mm active tip, PMF-21-100-5, Baylis Medical Inc.), which are carefully inserted until the needle tip reaches the upper edge of the intervertebral foramen. The parameters of PRF treatment will be set at 42 ℃, 2 Hz with 20 milliseconds current. The standardized drug treatment will include antiviral therapy, anticonvulsant treatment, three-step analgesic therapy

Trial Locations (1)

100070

Beijing Tiantan Hospital, Beijing

All Listed Sponsors
collaborator

Beijing Xiaotangshan Hospital

OTHER

collaborator

The First Hospital of Fangshan District,Beijing

OTHER

collaborator

Beijing Ditan Hospital

OTHER

collaborator

Hengshui People's Hospital

OTHER

lead

Beijing Tiantan Hospital

OTHER

NCT06914206 - Esketamine Combined With PRF of DRG for Acute/Subacute Zoster-associated Pain | Biotech Hunter | Biotech Hunter